Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Total Liabilities (2016 - 2026)

Standard Biotools has reported Total Liabilities over the past 16 years, most recently at $143.5 million for Q4 2025.

  • Quarterly Total Liabilities rose 2.02% to $143.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $143.5 million through Dec 2025, up 2.02% year-over-year, with the annual reading at $143.5 million for FY2025, 2.02% up from the prior year.
  • Total Liabilities was $143.5 million for Q4 2025 at Standard Biotools, up from $140.0 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $249.8 million in Q1 2022 and troughed at $125.0 million in Q1 2025.
  • The 5-year median for Total Liabilities is $163.5 million (2022), against an average of $168.9 million.
  • Year-over-year, Total Liabilities surged 37.07% in 2022 and then plummeted 37.61% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $180.6 million in 2021, then decreased by 11.13% to $160.5 million in 2022, then decreased by 0.41% to $159.9 million in 2023, then fell by 12.04% to $140.6 million in 2024, then grew by 2.02% to $143.5 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Total Liabilities are $143.5 million (Q4 2025), $140.0 million (Q3 2025), and $132.4 million (Q2 2025).